MeSH D054556 - venous thromboembolism
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Accord Healthcare | Apixaban | Apixaban Accord |  | 2020-07-23 |  |  |
| Rivaroxaban | Rivaroxaban Accord |  | 2020-11-16 |  |  | |
| Dabigatran etexilate | Dabigatran Etexilate Accord |  | 2023-05-26 |  |  | |
| Bayer | Rivaroxaban | Xarelto |  | 2008-09-30 |  |  |
| Berlin-Chemie | Edoxaban | Roteas |  | 2017-04-19 |  |  |
| Boehringer Ingelheim | Dabigatran etexilate | Pradaxa |  | 2008-03-17 |  |  |
| Bristol Myers Squibb | Apixaban | Eliquis |  | 2011-05-18 | $13,012 M | Q4/23-Q3/24 |
| Daiichi Pharmaceutical | Edoxaban | Lixiana |  | 2015-06-19 |  |  |
| Mylan | Rivaroxaban | Rivaroxaban Viatris (previously Rivaroxaban Mylan) |  | 2021-11-12 |  |  |
| Techdow Pharma Netherlands | Enoxaparin | Inhixa |  | 2016-09-15 |  |  |
Clinical Trials
Historical Success Rate
Phase 1
75%12/16
Phase 2
96%22/23
Phase 3
60%21/35
Approved: 6Overall Success rate: 43%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use